RT 3G

99,90 € Vial

5% off when paying with cryptocurrency

  • Synthetic 39-amino acid peptide characterized as an agonist at the GLP-1, GIP and glucagon receptors, supplied as a tool compound for receptor pharmacology research.
  • Structural modifications include Aib substitutions for reduced DPP-4 susceptibility and a C20 fatty diacid mediating reversible albumin binding.
  • Purity ≥99% (HPLC-verified), documented per batch in a lot-specific Certificate of Analysis.
  • Supplied as lyophilized powder, 10 mg per vial.
  • Research applications: receptor pharmacology across three target receptors, cAMP signal transduction, comparative agonism studies, analytical method development.
  • Store at −20 °C. For research use only. Not for human or veterinary use.
Quantity Price Discount
11-20 84,92 € Vial 15%
21+ 79,92 € Vial 20%

Delivery time: 1–6 Working Days

Add 70,00 € to cart and get free shipping!

Buy now

Description

RESEARCH USE ONLY. For laboratory research use only. Not a drug, food, cosmetic, or medical device. Not for human or veterinary use, diagnostic use, or any form of administration. Handling restricted to qualified personnel in a controlled laboratory environment.

Key Specifications

ParameterSpecification
TypeSynthetic triple hormone receptor agonist
Target ReceptorsGLP-1R, GIPR, GCGR
Sequence Length39 amino acids
Molecular FormulaC221H342N46O68
Molecular Weight4,731.4 Da
CAS Number2381089-83-2
Key ModificationsAib substitutions, C20 fatty diacid, C-terminal amide
FormLyophilized powder
AppearanceWhite to off-white lyophilized powder
Purity≥99% (HPLC), per batch-specific Certificate of Analysis
Quantity10 mg
Storage−20 °C

Product Overview

RT Peptide is a synthetic peptide characterized as an agonist at three metabolic receptor systems: the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR). This triple-receptor profile distinguishes it from mono- and dual-agonist reference compounds and makes it a tool for studying combined incretin and glucagon receptor engagement at the assay level.

The peptide carries Aib substitutions conferring resistance to DPP-4 cleavage, a C20 fatty diacid modification mediating reversible albumin binding, and C-terminal amidation.

Structural Modifications

  • Aib substitutions — non-coded α-aminoisobutyric acid residues whose quaternary α-carbon introduces steric hindrance at the DPP-4 recognition site.
  • C20 fatty diacid — attached at lysine via a γ-Glu linker, conferring reversible albumin binding. Extended plasma residence associated with this modification is described in published pharmacokinetic literature.
  • C-terminal amidation — the C-terminus is present as the carboxamide rather than the free acid.

Receptor Pharmacology

The following summarizes established receptor biology as reported in the scientific literature. It describes the receptor systems this reagent is used to investigate.

GLP-1R, GIPR and GCGR are class B G-protein-coupled receptors that couple to Gs and signal through adenylyl cyclase activation and intracellular cAMP accumulation.

ReceptorSignalling characterized in the literature
GLP-1RGs/cAMP/PKA signalling; glucose-dependent modulation of insulin secretion in beta-cell models
GIPRGs-coupled signalling characterized in beta-cell and adipocyte model systems
GCGRGs-coupled signalling characterized in hepatocyte models; hepatic glucose and lipid metabolism

Compounds engaging all three receptors are used in published in vitro research to study receptor cross-talk, relative potency and biased signalling across the three pathways.

Research Applications

Supplied as a reference standard and tool compound for in vitro and preclinical investigation.

  • Receptor Pharmacology — binding affinity determination across GLP-1R, GIPR and GCGR; cAMP accumulation assays; β-arrestin recruitment; receptor internalization kinetics; relative potency profiling.
  • Signal Transduction — Gs/cAMP/PKA pathway characterization in transfected cell lines, primary islet preparations and hepatocyte models.
  • Comparative Agonism — triple- versus dual- versus single-receptor engagement as a methodological comparator at the assay level.
  • Structure–Activity Studies — contribution of Aib substitution and lipidation to protease resistance and albumin binding in vitro.
  • Peptide Chemistry and Analytics — reference material for HPLC and MS method development, stability and degradation studies.

All applications are limited to controlled laboratory research environments.

Analytical Verification

Each batch is released against a lot-specific Certificate of Analysis documenting:

  • RP-HPLC — purity determination by optimized chromatographic separation
  • ESI-MS — molecular weight confirmation (4,731.4 Da) and sequence verification
  • Amino acid analysis — composition verification
  • Peptide content quantification
  • Residual solvent screening

Stability

ConditionData
Lyophilized, −20 °CStable for 24 months
Reconstituted solutionsReduced stability; store frozen in single-use aliquots
Light exposureProtect from light
Freeze–thawAvoid repeated cycles

Regulatory Status

RT Peptide is not authorised as a medicinal product in the EU, the United States, or any other jurisdiction. It is supplied exclusively as a research reagent for laboratory use and is not placed on the market for therapeutic, diagnostic or consumer applications.

Frequently Encountered Inquiries

How does RT Peptide differ from incretin agonists targeting fewer receptors?
RT Peptide engages GLP-1R, GIPR and GCGR. Dual agonists engage two of these and mono-agonists one. This makes it useful as a comparator in receptor-level studies of multi-receptor engagement and cross-talk.

What is the purpose of the Aib substitutions?
The quaternary α-carbon of α-aminoisobutyric acid sterically hinders DPP-4 cleavage, a well-characterized approach to improving peptide stability in vitro.

What does the C20 fatty diacid modification do?
The acyl chain, attached through a γ-Glu linker, mediates reversible albumin binding — a structural strategy described in the peptide chemistry literature for extending plasma residence.

What storage conditions are required?
Lyophilized material is stable for 24 months at −20 °C. Reconstituted solutions show reduced stability and should be aliquoted and stored frozen. Protect from light and avoid repeated freeze–thaw cycles.

Is a Certificate of Analysis provided?
Yes. Each batch ships with a lot-specific CoA documenting HPLC purity, MS identity confirmation and peptide content.

Additional information
Dosage10mg, 20mg, 40mg, 50mg, 5mg
Product safety

Product safety

Safety instructions

SAFETY DATA SHEET (SDS)

RT Peptide — Research-Grade Lyophilized Powder (RUO)

CAS Number: 2381089-83-2
Synonyms: GLP-1/GIP/glucagon triple receptor agonist
REACH: Not subject to registration at quantities below 1 tonne per year (scientific research and development)

SECTION 1 — Identification

1.1 Product Identifier: RT Peptide — Lyophilized Powder
CAS 2381089-83-2 · EC number: not assigned · Index number: not assigned

1.2 Identified Uses: Analytical-grade peptide for in-vitro laboratory research. Research Use Only (RUO).
Uses advised against: Human or veterinary use, administration in any form, diagnostic use, food, cosmetic or consumer applications.

1.3 Supplier:
BIONIX RESEARCH — [legal entity]
[full postal address — required]
[telephone number — required]
info@bionixresearch.com

1.4 Emergency Telephone: [24 h emergency / national poison centre — required]
General emergency (EU): 112

SECTION 2 — Hazards Identification

2.1 Classification: Based on available data, the classification criteria of Regulation (EC) No 1272/2008 (CLP) are not met. No GHS pictograms, signal word or hazard statements required.

2.2 Label elements: None required under CLP.

2.3 Other hazards:

  • Pharmacologically active compound — handle with appropriate care
  • Avoid dust formation and inhalation
  • Avoid contact with eyes and skin
  • Laboratory use only
  • Not assessed as PBT or vPvB (no data available)

SECTION 3 — Composition / Information on Ingredients

Substance (not a mixture).

PropertyValue
SubstanceRT Peptide
CAS2381089-83-2
EC numberNot assigned
Molecular FormulaC221H342N46O68
Molecular Weight4,731.4 Da
Purity≥99% (HPLC)
FormLyophilized powder
Structure39-amino acid peptide with Aib substitutions and C20 fatty diacid modification
ImpuritiesNone present at concentrations requiring classification

SECTION 4 — First-Aid Measures

Inhalation: Move to fresh air. Rinse mouth and nose. Seek medical attention if symptoms persist.

Skin Contact: Remove contaminated clothing. Wash affected area thoroughly with soap and water. Seek medical attention if irritation develops or persists.

Eye Contact: Rinse cautiously with clean water for at least 15 minutes. Remove contact lenses if present and easy to do. Continue rinsing. Seek medical attention if irritation persists.

Ingestion: Rinse mouth thoroughly. Do not induce vomiting. Seek medical advice immediately due to pharmacological activity.

Most important symptoms: Accidental systemic exposure may produce pharmacological effects, including nausea, gastrointestinal disturbance and disturbances of glucose homeostasis.

Notes to Physician: This substance is a pharmacologically active agonist at GLP-1, GIP and glucagon receptors. Treat symptomatically. Monitor blood glucose following significant exposure — glucagon receptor engagement may affect glucose homeostasis in either direction. No specific antidote available.

SECTION 11 — Toxicological Information

Acute Toxicity: No toxicological data available for this material. Low acute toxicity anticipated based on peptide nature.

Routes of Exposure:

  • Inhalation: Dust may cause respiratory tract irritation
  • Skin: May cause mild irritation; systemic absorption of a pharmacologically active compound cannot be excluded
  • Eyes: May cause irritation
  • Ingestion: May cause gastrointestinal effects; pharmacological activity possible

Pharmacological Activity: This substance is a potent agonist at GLP-1, GIP and glucagon receptors. Activation of these receptor systems is associated in the literature with modulation of insulin and glucagon secretion, gastric motility and hepatic glucose metabolism. Accidental exposure may therefore result in pharmacological effects, including nausea, gastrointestinal disturbance and altered glucose homeostasis.

Chronic Toxicity: No data available.
Carcinogenicity: No data available for this substance. Not listed by IARC, NTP or OSHA.
Germ Cell Mutagenicity: No data available.
Reproductive Toxicity: No data available.
STOT (single / repeated exposure): No data available.
Aspiration Hazard: Not applicable.

SECTION 5 — Fire-Fighting Measures

Extinguishing Media: CO2, dry chemical, foam, or water spray.
Unsuitable Media: None known.
Specific Hazards: Organic peptide powder; non-flammable under normal conditions. Thermal decomposition may release carbon monoxide, carbon dioxide and nitrogen oxides.
Firefighter Protection: Self-contained breathing apparatus and full protective clothing.

SECTION 6 — Accidental Release Measures

Personal Precautions: Avoid dust formation. Wear appropriate PPE including gloves, respiratory protection and eye protection. Ensure adequate ventilation.
Environmental Precautions: Prevent release into drains, waterways or soil.
Containment / Cleanup: Collect powder carefully using appropriate tools, avoiding dust generation. Transfer to a sealed, labelled waste container. Clean contaminated surfaces with water.

SECTION 7 — Handling and Storage

Handling:

  • Use only in laboratory settings with appropriate engineering controls
  • Minimize dust formation
  • Wear standard PPE (gloves, lab coat, eye protection)
  • Avoid inhalation, ingestion and skin contact
  • Handle powder in a fume hood or well-ventilated area
  • Wash hands thoroughly after handling

Storage:

  • Store at −20 °C in the original sealed vial
  • Protect from light, heat and humidity
  • Keep container tightly closed
  • Store away from oxidizing agents
  • Research use only

Reconstituted solutions: Reduced stability compared with lyophilized material. Store refrigerated (2–8 °C) for short-term handling, or aliquot and store frozen. Protect from light. Avoid repeated freeze–thaw cycles.

SECTION 8 — Exposure Controls / Personal Protection

Exposure Limits: No occupational exposure limits established.
Engineering Controls: Local exhaust ventilation or fume hood when handling powder.

ProtectionRecommendation
HandsNitrile gloves (double gloving recommended)
EyesSafety glasses or goggles to EN 166
SkinLab coat, long sleeves
RespiratoryFFP2/N95 or higher when handling powder

Hygiene Measures: Wash hands thoroughly after handling. Do not eat, drink or smoke in the work area.

SECTION 9 — Physical and Chemical Properties

PropertyValue
AppearanceWhite to off-white lyophilized powder
OdourNone
Odour thresholdNot determined
Melting pointNot determined (decomposes before melting)
Boiling pointNot applicable
Flash pointNot applicable
Evaporation rateNot applicable
FlammabilityNot classified as flammable
Vapour pressure / densityNot applicable
Relative densityNot determined
SolubilitySoluble in aqueous buffers
Partition coefficient (log Pow)Not determined
Auto-ignition temperatureNot determined
Decomposition temperatureNot determined
ViscosityNot applicable
Explosive / oxidising propertiesNone expected
StabilityStable at −20 °C; sensitive to heat and moisture

SECTION 10 — Stability and Reactivity

Reactivity: No hazardous reactions under normal conditions of use.
Chemical Stability: Stable under recommended storage conditions (−20 °C, sealed, protected from light).
Conditions to Avoid: Heat, moisture, air exposure, repeated freeze–thaw cycles, prolonged light exposure.
Incompatible Materials: Strong oxidizing agents, strong acids, strong bases.
Hazardous Decomposition Products: Carbon monoxide, carbon dioxide, nitrogen oxides.

SECTION 12 — Ecological Information

Ecotoxicity: No data available. Significant environmental risk not expected at research quantities.
Persistence / Degradability: Expected to be biodegradable as a peptide. No test data available.
Bioaccumulative Potential: Not expected to bioaccumulate.
Mobility in Soil: Water soluble; may be mobile in soil.
PBT / vPvB Assessment: Not performed; no data available.
Other Adverse Effects: Prevent release into water systems, drains or soil.

SECTION 13 — Disposal Considerations

Disposal Method: Dispose in accordance with local, regional and national regulations for laboratory chemical waste and pharmacologically active compounds.
Contaminated Packaging: Dispose as chemical waste. Do not reuse containers.
Special Precautions: Do not dispose via household waste or sewer systems. Incineration at a licensed facility is recommended.

SECTION 14 — Transport Information

RegulationClassification
ADR (Road)Not regulated
IMDG (Sea)Not regulated
IATA (Air)Not regulated
UN NumberNot assigned
Proper Shipping NameNot applicable
Hazard ClassNot applicable
Packing GroupNot applicable
Environmental hazardsNot classified as marine pollutant

Special Precautions: Ship in an insulated container with cold packs. Label as "Research Use Only — Not for Human Use".

SECTION 15 — Regulatory Information

EU Regulations:

  • Not subject to registration under REACH (EC) No 1907/2006 at quantities below 1 tonne per year
  • Based on available data, does not meet the classification criteria of CLP Regulation (EC) No 1272/2008
  • Not authorised as a medicinal product in the EU. Supplied exclusively as a research reagent and not placed on the market for therapeutic use.

Other Regulations:

  • Not a controlled substance
  • Not listed under the Rotterdam Convention
  • Not listed under the Stockholm Convention

Chemical Safety Assessment: Not performed.

Product Status: Research Use Only. Not approved for human or veterinary therapeutic, diagnostic or cosmetic applications.

SECTION 16 — Other Information

Revision Date: [insert date]
Version: 1.1 — supersedes version 1.0

Abbreviations: CLP — Classification, Labelling and Packaging · GHS — Globally Harmonized System · PPE — Personal Protective Equipment · RUO — Research Use Only · HPLC — High-Performance Liquid Chromatography · Aib — α-Aminoisobutyric acid · PBT — Persistent, Bioaccumulative, Toxic · vPvB — very Persistent, very Bioaccumulative · STOT — Specific Target Organ Toxicity

References: CLP Regulation (EC) No 1272/2008 · REACH Regulation (EC) No 1907/2006

Disclaimer: This Safety Data Sheet is intended for trained laboratory personnel handling research-grade materials. The information is based on current knowledge at the date of issue. It does not signify suitability for therapeutic, diagnostic or consumer applications. Users must make their own assessment of the material's suitability for their specific purposes.

BIONIX RESEARCH — info@bionixresearch.com
For Research Use Only. Not for human or veterinary use.

Storage

STORAGE AND HANDLING

Lyophilized Peptide Stability

All BIONIX Research products are manufactured using lyophilization — a pharmaceutical-industry freeze-drying process that creates a stable crystalline structure, removing approximately 95% of moisture from the peptide compound.

This technology ensures up to 3-4 months of stability at ambient temperatures during shipping and storage. The result: a pure, puffy white powder that maintains structural integrity until reconstitution, regardless of logistical conditions.

ConditionDuration
-20°CUp to 24 months
2-8°CUp to 3 months (short-term)

Protect from light and moisture. The lyophilized state prevents hydrolytic degradation and maintains peptide bond integrity.

Reconstitution Protocol:

  • Solvent: Sterile bacteriostatic water or appropriate buffer
  • Technique: Add solvent slowly along vial wall
  • Mixing: Gently swirl until dissolved—do not shake or vortex (shear forces damage peptide bonds)
  • Sterility: Maintain aseptic conditions throughout

Post-Reconstitution Storage: 

  • 2-8°C: Use within 4 weeks
  • Aliquot and freeze at -20°C for extended storage
  • Avoid repeated freeze-thaw cycles
  • Protect from light and moisture

The 3-Tier Storage Protocol

STABLE - Prewritten Phase (Up to 4 Months) Unreconstituted lyophilized peptides remain chemically stable at room temperature (15-25°C) for 3-4 months when stored away from direct sunlight and moisture. The sealed vacuum packaging provides oxidative protection during this window.

FRESH - Active Phase (Up to 30 Days) Once reconstituted with bacteriostatic water, immediate refrigeration at 2-8°C is required. Stability degrades rapidly above this threshold — refrigerate within 30 minutes of reconstitution for optimal preservation.

PRESERVATION - Long-Term Phase (6-12 Months+) For extended storage beyond 30 days, transfer to -20°C (standard freezer, not frost-free). At this temperature, most reconstituted peptides maintain stability for 6-12 months. Note: Avoid freeze-thaw cycles — each temperature fluctuation degrades peptide bonds.

Quality Indicators to Monitor

  • Visual inspection: Solution should remain clear; cloudiness indicates degradation
  • Precipitation: Particulates signal protein denaturation — discard immediately
  • Temperature logs: Use a calibrated thermometer; refrigerator door storage fluctuates more than back shelves
  • Time tracking: Label each vial with reconstitution date — 30-day countdown begins at mixing

Handling Best Practices

Store peptides in their original amber vials until reconstitution. Post-reconstitution: dark glass, light-blocking storage containers recommended. Never expose vials to direct sunlight or UV light — photodegradation occurs within hours.

For detailed Complete Peptide Storage Protocol access our Guide. Complete Peptide Storage Protocol

Legal Notice

This product is intended exclusively for laboratory research. Not approved for human use, not for therapeutic applications, and not for in vivo studies in humans.

The buyer confirms that this product will be used exclusively for research purposes in an appropriate laboratory environment.

Frequently bought together

99,90 € Vial
49,90 € Vial
69,90 € Vial
219,70 €
For 2 items